p53/p63/p73 isoforms: An orchestra of isoforms to harmonise cell differentiation and response to stress

Cell Death and Differentiation

Volumn 13, Issue 6, 2006, Pages 962-972

  Murray Zmijewski, F ^a   Lane, D P ^a   Bourdon, J C ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Cancer; Development; Drosophila; Promoter; Splice; Zebrafish

Indexed keywords

DNA; ISOPROTEIN; PROTEIN P53; PROTEIN P63; PROTEIN P73; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

BLADDER CANCER; BRAIN MALFORMATION; BREAST CANCER; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL ACTIVITY; CELL CYCLE; CELL DIFFERENTIATION; CLEFT LIP FACE PALATE; DNA BINDING; DROSOPHILA; EAR MALFORMATION; ECTODERMAL DYSPLASIA; EYELID DISEASE; FOOT MALFORMATION; GENE ACTIVITY; GENE MUTATION; GENE STRUCTURE; GENETIC CODE; GENETIC CONSERVATION; HAND MALFORMATION; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; LUNG CARCINOMA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NEUROBLASTOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PHASE TRANSITION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; STRESS; TOOTH MALFORMATION; TRANSLATION INITIATION; UROGENITAL TRACT MALFORMATION; UTERINE CERVIX CARCINOMA; ZEBRA FISH;

ALTERNATIVE SPLICING; ANIMALS; APOPTOSIS REGULATORY PROTEINS; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; DNA; DNA-BINDING PROTEINS; EVOLUTION, MOLECULAR; HUMANS; MICE; MICE, KNOCKOUT; MUTATION; NEOPLASMS; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); PROMOTER REGIONS, GENETIC; PROTEIN ISOFORMS; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

DANIO RERIO;

EID: 33646798450     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401914     Document Type: Review

References (75)

1. Lane DP and Crawford LV (1979) T antigen is bound to a host protein in SV40-transformed cells. Nature 278: 261-263.
2. Linzer DIH and Levine AJ (1979) Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and in infected embryonal carcinoma cells. Cell 1: 43-52.
3. Melero JA, Stitt DT, Mangel WF and Carroll RB (1979) Identification of new polypeptide species (48-55 K) immunoprecipitable by antiserum to purified large T antigen and present in simian virus 40-infected and transformed cells. J. Virol. 93: 466-480.
4. Kress M, May E, Cassingena R and May P (1979) Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum. J. Virol. 31: 472-483.
5. De Leo AB, Jay G, Appella E, Dubois GC, Law LW and Old LJ (1979) Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc. Natl. Acad. Sci. USA 76: 2420-2424.
6. Oren M (2003) Decision making by p53: Life, death and cancer. Cell Death Differ. 10: 431-442.
7. Lane DP (1992) Cancer. p53, guardian of the genome (news; comment) (see comments). Nature 358: 15-16.
8. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW and Vogelstein B (1992) Definition of a consensus binding site for p53. Nat. Genet. 1: 45-49.
9. Bourdon JC, Deguin-Chambon V, Lelong JC, Dessen P, May P, Debuire B and May E (1997) Further characterisation of the p53 responsive element - identification of new candidate genes for trans-activation by p53. Oncogene 14: 85-94.
10. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
11. Nakano K and Vousden KH (2001) PUMA, a novel proapoptotic gene, is induced by p53. Mol. cell. 7: 683-694.
12. Bourdon JC, Renzing J, Robertson PL, Fernandes KN and Lane DP (2002) Scotin, a novel p53-inducible proapoptotic protein located in the ER and the nuclear membrane. J. Cell. Biol. 158: 235-246.
13. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D and McKeon F (1998) p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2: 305-316.
14. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F and Caput D (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809-819.
15. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK and Lane DP (2005) p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 19: 2122-2137.
16. Stamm S, Ben-Ari S, Rafalska I, Tang Y, Zhang Z, Toiber D, Thanaraj TA and Soreq H (2005) Function of alternative splicing. Gene 344: 1-20.
17. McKeon F (2004) p63 and the epithelial stem cell: More than status quo? Genes Dev. 18: 465-469.
18. Osada M, Park HL, Nagakawa Y, Yamashita K, Fomenkov A, Kim MS, Wu G, Nomoto S, Trink B and Sidransky D (2005) Differential recognition of response elements determines target gene specificity for p53 and p63. Mol. Cell. Biol. 25: 6077-6089.
19. Sasaki Y, Naishiro Y, Oshima Y, Imai K, Nakamura Y and Tokino T (2005) Identification of pigment epithelium-derived factor as a direct target of the p53 family member genes. Oncogene 24: 5131-5136.
20. Benard J, Douc-Rasy S and Ahomadegbe JC (2003) TP53 family members and human cancers. Hum. Mutat. 21: 182-191.
21. Dohn M, Zhang S and Chen X (2001) p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 20: 3193-3205.
22. Wu G, Nomoto S, Hoque MO, Dracheva T, Osada M, Lee CC, Dong SM, Guo Z, Benoit N, Cohen Y, Rechthand P, Califano J, Moon CS, Ratovitski E, Jen J, Sidransky D and Trink B (2003) DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res. 63: 2351-2357.
23. Koster MI, Kim S, Mills AA, DeMayo FJ and Roop DR (2004) p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev. 18: 126-131.
24. Mills AA (2006) p63: Oncogene or tumor suppressor? Curr. Opin. Genet. Dev. 16: 38-44.
25. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D, Yang A, McKeon F and Jacks T (2005) Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7: 363-373.
26. Keyes WM, Wu Y, Vogel H, Guo X, Lowe SW and Mills AA (2005) p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev. 19: 1986-1999.
27. Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME, Westfall MD, Roberts JR, Pietenpol JA, Carbone DP and Gonzalez AL (2003) Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res. 63: 7113-7121.
28. Wang TY, Chen BF, Yang YC, Chen H, Wang Y, Cviko A, Quade BJ, Sun D, Yang A, McKeon FD and Crum CP (2001) Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: A study of 250 cases. Hum. Pathol. 32: 479-486.
29. Pruneri G, Fabris S, Dell'Orto P, Biasi MO, Valentini S, Del Curto B, Laszlo D, Cattaneo L, Fasani R, Rossini L, Manzotti M, Bertolini F, Martinelli G, Neri A and Viale G (2005) The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification. J. Pathol. 206: 337-345.
30. Nylander K, Vojtesek B, Nenutil R, Lindgren B, Roos G, Zhanxiang W, Sjostrom B, Dahlqvist A and Coates PJ (2002) Differential expression of p63 isoforms in normal tissues and neoplastic cells. J. Pathol. 198: 417-427.
31. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR and Bradley A (1999) p63 is a p53 homologue required for limb and epidermal morphogenesis (in Process Citation). Nature 398: 708-713.
32. Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, Smits AP, Newbury-Ecob R, Hennekam RC, Van Buggenhout G, van Haeringen A, Woods CG, van Essen AJ, de Waal R, Vriend G, Haber DA, Yang A, McKeon F, Brunner HG and van Bokhoven H (1999) Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell 99: 143-153.
33. van Bokhoven H, Hamel BC, Bamshad M, Sangiorgi E, Gurrieri F, Duijf PH, Vanmolkot KR, van Beusekom E, van Beersum SE, Celli J, Merkx GF, Tenconi R, Fryns JP, Verloes A, Newbury-Ecob RA, Raas-Rotschild A, Majewski F, Beemer FA, Janecke A, Chitayat D, Crisponi G, Kayserili H, Yates JR, Neri G and Brunner HG (2001) p63 Gene mutations in eec syndrome, limb-mammary syndrome, and isolated split handsplit foot malformation suggest a genotype-phenotype correlation. Am. J. Hum. Genet. 69: 481-492.
34. Duijf PH, Vanmolkot KR, Propping P, Friedl W, Krieger E, McKeon F, Dotsch V, Brunner HG and van Bokhoven H (2002) Gain-of-function mutation in ADULT syndrome reveals the presence of a second transactivation domain in p63. Hum. Mol. Genet. 11: 799-804.
35. McGrath JA, Duijf PH, Doetsch V, Irvine AD, de Waal R, Vanmolkot KR, Wessagowit V, Kelly A, Atherton DJ, Griffiths WA, Orlow SJ, van Haeringen A, Ausems MG, Yang A, McKeon F, Bamshad MA, Brunner HG, Hamel BC and van Bokhoven H (2001) Hay-Wells syndrome is caused by heterozygous missense mutations in the SAM domain of p63. Hum. Mol. Genet. 10: 221-229.
36. Moll UM and Slade N (2004) p63 and p73: Roles in development and tumor formation. Mol. Cancer Res. 2: 371-386.
37. Melino G, Lu X, Gasco M, Crook T and Knight RA (2003) Functional regulation of p73 and p63: Development and cancer. Trends Biochem. Sci. 28: 663-670.
38. Stiewe T, Zimmermann S, Frilling A, Esche H and Putzer BM (2002) Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res. 62: 3598-3602.
39. Liu G, Nozell S, Xiao H and Chen X (2004) DeltaNp73beta is active in transactivation and growth suppression. Mol. Cell. Biol. 24: 487-501.
40. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR and Miller FD (2000) An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289: 304-306.
41. Saifudeen Z, Diavolitsis V, Stefkova J, Dipp S, Fan H and El-Dahr SS (2005) Spatiotemporal switch from DeltaNp73 to TAp73 isoforms during nephrogenesis: Impact on differentiation gene expression. J. Biol. Chem. 280: 23094-23102.
42. De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M, Levrero M and Melino G (1998) Two new p73 splice variants, gamma and delta, with different transcriptional activity. J. Exp. Med. 188: 1763-1768.
43. Tschan MP, Grob TJ, Peters UR, Laurenzi VD, Huegli B, Kreuzer KA, Schmidt CA, Melino G, Fey MF, Tobler A and Cajot JF (2000) Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemia. Biochem. Biophys. Res. Commun. 277: 62-65.
44. De Laurenzi V, Rossi A, Terrinoni A, Barcaroli D, Levrero M, Costanzo A, Knight RA, Guerrieri P and Melino G (2000) p63 and p73 transactivate differentiation gene promoters in human keratinocytes. Biochem. Biophys. Res. Commun. 273: 342-346.
45. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F and Caput D (2000) p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404: 99-103.
46. Fillippovich I, Sorokina N, Gatei M, Haupt Y, Hobson K, Moallem E, Spring K, Mould M, McGuckin MA, Lavin MF and Khanna KK (2001) Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53. Oncogene 20: 514-522.
47. Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H, Daxenbichler G, Zeimet A, Zeillinger R, Marth C and Moll UM (2004) Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res. 64: 2449-2460.
48. Casciano I, Mazzocco K, Boni L, Pagnan G, Banelli B, Allemanni G, Ponzoni M, Tonini GP and Romani M (2002) Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ. 9: 246-251.
49. Flaman J-M, Waridel F, Estreicher A, Vannier A, Limacher J-M, Gilbert D, Iggo R and Frebourg T (1996) The human tumor suppressor gene p53 is alternatively spliced in normal cells. Oncogene 12: 813-818.
50. Chow VT, Quek HH and Tock EP (1993) Alternative splicing of the p53 tumor suppressor gene in the Molt-4 T-lymphoblastic leukemia cell line. Cancer Lett. 73: 141-148.
51. Yin Y, Stephen CW, Luciani MG and Fahraeus R (2002) p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat. Cell Biol. 4: 462-467.
52. Ghosh A, Stewart D and Matlashewski G (2004) Regulation of human p53 activity and cell localization by alternative splicing. Mol. Cell Biol. 24: 7987-7997.
53. Zhu J, Zhou W, Jiang J and Chen X (1998) Identification of a novel p53 functional domain that is necessary for mediating apoptosis. J. Biol. Chem. 273: 13030-13036.
54. Mills AA (2005) p53: Link to the past, bridge to the future. Genes Dev. 19: 2091-2099.
55. Rohaly G, Chemnitz J, Dehde S, Nunez AM, Heukeshoven J, Deppert W and Domreiter I (2005) A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint. Cell 122: 21-32.
56. Ollmann M, Young LM, Di Como CJ, Karim F, Belvin M, Robertson S, Whittaker K, Demsky M, Fisher WW, Buchman A, Duyk G, Friedman L, Prives C and Kopczynski C (2000) Drosophila p53 is a structural and functional homolog of the tumor suppressor p53. Cell 101: 91-101.
57. Brodsky MH, Nordstrom W, Tsang G, Kwan E, Rubin GM and Abrams JM (2000) Drosophila p53 binds a damage response element at the reaper locus. Cell 101: 103-113.
58. Chen J, Ruan H, Ng SM, Gao C, Soo HM, Wu W, Zhang Z, Wen Z, Lane DP and Peng J (2005) Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish. Genes Dev. 19: 2900-2911.
59. Wolf D, Admon S, Oren M and Rotter V (1984) Abelson murine leukemia virus-transformed cells that lack p53 protein synthesis express aberrant p53 mRNA species. Mol. Cell Biol. 4: 552-558.
60. Almog N, Goldfinger N and Rotter V (2000) p53-dependent apoptosis is regulated by a C-terminally alternatively spliced form of murine p53. Oncogene 19: 3395-3403.
61. Wu Y, Liu Y, Lee L, Miner Z and Kulesz-Martin M (1994) Wild-type aternatively spliced p53: Binding to DNA and interaction with the major p53 protein in vitro and in cells. EMBO J. 13: 4823-4830.
62. Laverdiere M, Beaudoin J and Lavigueur A (2000) Species-specific regulation of alternative splicing in the C-terminal region of the p53 tumor suppressor gene. Nucleic Acids Res. 28: 1489-1497.
63. Will K, Warnecke G, Bergmann S and Deppert W (1995) Species- and tissue-specific expression of the C-terminal alternatively spliced form of the tumor suppressor p53. Nucleic Acids Res. 23: 4023-4028.
64. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS and Bradley A (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221.
65. Armstrong JF, Kaufman MH, Harrison DJ and Clarke AR (1995) High-frequency developmental abnormalities in p53-deficient mice. Curr. Biol. 5: 931-936.
66. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT and Jacks T (1995) A subset of p53-deficient embryos exhibit exencephaly. Nat. Genet. 10: 175-180.
67. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, Lu X, Soron G, Cooper B, Brayton C, Hee Park S, Thompson T, Karsenty G, Bradley A and Donehower LA (2002) p53 mutant mice that display early ageing-associated phenotypes. Nature 415: 45-53.
68. Maier B, Gluba W, Bernier B, Turner T, Mohammad K, Guise T, Sutherland A, Thomer M and Scrable H (2004) Modulation of mammalian life span by the short isoform of p53. Genes Dev. 18: 306-319.
69. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK and Lozano G (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861-872.
70. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D and Jacks T (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847-860.
71. Garcia-Cao I, Garcia-Cao M, Martin-Caballero J, Criado LM, Klatt P, Flores JM, Weill JC, Blasco MA and Serrano M (2002) 'Super p53' mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 21: 6225-6235.
72. Clore GM, Ernst J, Clubb R, Ornichinski JG, Kennedy WM, Sakaguchi K, Appella E and Gronenbom AM (1995) Refined solution structure of the oligomerization domain of the tumour suppressor p53 (see comments). Nat. Struct. Biol. 2: 321-333.
73. Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L, Levine AJ, Sacchi A, Cesareni G, Oren M and Blandino G (2000) Physical and functional interaction between p53 mutants and different isoforms of p73. J. Biol. Chem. 275: 29503-29512.
74. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F and Jacks T (2002) p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416: 560-564.
75. Grob TJ, Novak U, Maisse C, Barcaroli D, Luthi AU, Pimia F, Hugli B, Graber HU, De Laurenzi V, Fey MF, Melino G and Tobler A (2001) Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ. 8: 1213-1223.